Skip to main content

Sionna Therapeutics

Sionna Therapeutics Inc is an American clinical-stage biopharmaceutical company developing small molecule medicines to treat cystic fibrosis. The company discovers and advances small molecule modulators engineered to fully restore the function of the NBD1 domain of the CFTR protein, addressing the underlying genetic cause of cystic fibrosis. Main revenue drivers currently comprise investment capital financing, research grants, and potential milestone licensing fees as Phase I/II clinical trials advance. Sionna Therapeutics targets pulmonologists, cystic fibrosis clinical centers, biopharmaceutical research collaborators, and cystic fibrosis patients across North America and Europe. The company holds an innovative position in next-generation CFTR NBD1-directed small molecule drug discovery. Headquartered in Boston, Massachusetts, Sionna Therapeutics Inc operates as a private biopharmaceutical enterprise.

3 of the funds FundTelligence covers report a position in Sionna Therapeutics.

Legal name
Sionna Therapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
3

Funds holding Sionna Therapeutics

Loading...